Optimized PROM1 Gene Sequence for Retinitis Pigmentosa AAV Vector
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for retinitis pigmentosa have low expression levels of the PROM1 protein, leading to ineffective treatment of hereditary retinal degeneration.
Innovation Solution
A recombinant adeno-associated virus (AAV) vector expressing the optimized human PROM1 protein is developed, utilizing a nucleotide sequence with enhanced expression efficiency, specifically designed for mammalian cells, including photoreceptor cells, to treat retinitis pigmentosa and restore vision.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a conventional AAV vector expressing unoptimized PROM1 sequence is used, then the gene therapy can be administered, but the expression level of PROM1 protein is low, resulting in ineffective treatment
Solution Approach 1:
The patent optimizes the nucleotide sequence of the PROM1 gene to improve expression levels. Specifically, the coding sequence is optimized for mammalian cells including photoreceptor cells, changing the genetic parameters to achieve higher protein expression while maintaining the same therapeutic function. This resolves the contradiction by modifying the sequence parameters to simultaneously achieve both adequate expression levels and therapeutic effectiveness.
2Reliability
If the nucleotide sequence of PROM1 is optimized for enhanced expression, then therapeutic efficacy is improved, but the sequence design becomes more complex
Solution Approach 1:
The patent applies sequence optimization techniques that modify nucleotide parameters while preserving the amino acid sequence. This involves changing synonymous codons, adjusting GC content, and optimizing for mammalian translation machinery without altering the protein structure. The complexity is managed through systematic computational design rather than trial-and-error approaches.
Solution Approach 2:
The patent creates an optimized copy of the PROM1 nucleotide sequence that maintains the same protein-coding function but with improved expression characteristics. The optimized sequence is a replica with modified parameters, allowing the same therapeutic protein to be produced at higher levels without requiring new protein design.
3Reliability
If gene therapy is administered to treat retinitis pigmentosa, then photoreceptor cell function can be restored, but the treatment is only effective if expression levels are sufficient
Solution Approach 1:
The patent optimizes the PROM1 gene sequence parameters specifically for mammalian and photoreceptor cell expression systems. This includes optimizing codon usage bias, adjusting mRNA secondary structure, and enhancing promoter compatibility to achieve sufficient protein expression levels that can restore photoreceptor function in treated animals.
Data Source
AI summary
Provided, in an aspect, is a gene therapy vector, such as for treating retinitis pigmentosa. In an embodiment, a target specific optimization design is performed on a PROM1 gene coding sequence to obtain a nucleotide sequence particularly suitable for efficiently expressing a PROM1 protein in a mammalian cell, and a recombinant AAV virus for expressing a normal human PROM1 protein is constructed. Compared with a coding sequence which is not optimized, the expression level of the optimized PROM1 coding sequence (SEQ ID NO.:1) is increased more than three times. The sequence is particularly suitable for expression in a mammalian cell.